Oryzon Genomics S.A. (ORN)
Summary
ORN Chart
Oryzon Genomics S.A. (ORN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Oryzon Genomics S.A. ever had a stock split?
Oryzon Genomics S.A. Profile
| Biotechnology Industry | Healthcare Sector | Carlos Manuel Buesa Arjol CEO | XMUN Exchange | ES0167733015 ISIN |
| ES Country | 47 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Oryzon Genomics S.A. is a pioneering biopharmaceutical entity immersed in the field of epigenetics for innovating treatments geared towards individuals suffering from cancer and central nervous system (CNS) disorders. Stepping into the clinical stage, this company dedicates its resources to the discovery and evolution of groundbreaking therapeutics that leverage the principles of epigenetics. Established in the year 2000 and strategically headquartered in Cornellà de Llobregat, Spain, Oryzon has been at the forefront of translating scientific insights into clinically relevant therapies. Their commitment is to address the unmet medical needs of patients through their robust research and development programs, which are primarily focused on oncology and neurologic diseases.
Products and Services
Within its therapeutic pipeline, Oryzon Genomics S.A. has developed several promising drug candidates, including:
- Iadademstat (ORY-1001): This is a highly selective inhibitor of LSD1, a crucial enzyme involved in the regulation of gene expression. Iadademstat is currently progressing through Phase II clinical trials aimed at treating various cancer types. Its mechanism of action involves altering the chromatin structure to modulate gene expression, thereby potentially inhibiting the proliferation of cancer cells and inducing their death.
- Vafidemstat (ORY-2001): Tailored for the central nervous system, this CNS-optimized LSD1 inhibitor is also in Phase II clinical trials. Vafidemstat is being explored for its potential in treating a range of CNS and psychiatric disorders. By targeting specific epigenetic mechanisms, it aims to restore normal function and structure in the brains of patients, offering a new avenue for the treatment of neurological conditions.
- ORY-3001: Still in the preclinical development stage, ORY-3001 is another LSD1 inhibitor crafted by Oryzon. Unlike its predecessors, this compound is being investigated for its therapeutic potential in non-oncological diseases. The focus on ORY-3001 underlines Oryzon's commitment to expanding the therapeutic applications of epigenetics beyond cancer, showcasing their dedication to exploring uncharted territories in medicine.
